首页 > 市场调查报告书 > 製药

生技设备生物工艺

北美生物加工市场预测至 2031 年 - 区域分析 - 按产品、营运规模、製程、应用和最终用户

市场调查报告书

商品编码

1597070

北美生物加工市场预测至 2031 年 - 区域分析 - 按产品、营运规模、製程、应用和最终用户

North America Bioprocessing Market Forecast to 2031 - Regional Analysis - by Product, Scale of Operation, Process, Application, and End User

出版日期: 2024年10月03日 | 出版商:

The Insight Partners | 英文 151 Pages | 订单完成后即时交付

价格

简介目录图表

2023年北美生物加工市场价值为124.406亿美元，预计到2031年将达到359.5043亿美元；预计2023年至2031年复合年增长率为14.2%。

慢性病盛行率的增加推动了北美生物加工市场

老年人久坐的生活增加了肥胖和糖尿病等生活方式障碍的盛行率。遗传基因也可以表达这些疾病以及其他健康问题，例如心血管疾病（CVD）、阿兹海默症和忧郁症。据国家老化委员会称，80% 的成年人（65 岁及以上）一生中至少患有一种慢性病。根据美国疾病管制与预防中心(CDC) 的数据，2020 年，美国大约每10 人中就有6 人患有至少一种严重疾病，每10 人中就有4 人患有两种或两种以上慢性病。 2015 年至2050 年间，全球60 岁以上人口的比例将几乎翻倍，从12% 增至22%。有关。因忙碌的生活方式而引起的心绞痛、动脉粥状硬化和急性心肌梗塞等心血管疾病是全世界死亡的重要原因之一。根据世界心臟基金会的数据，在过去 30 年（1990 年至 2020 年）中，CVD 引起的死亡率激增了 60%。 2021 年，有 2,050 万人因心血管疾病死亡。糖尿病是危及生命的慢性疾病之一，尚无功能性治癒方法。所有类型的糖尿病都会在不同的身体部位引起各种併发症，增加整体死亡风险。根据国际糖尿病联盟的数据，北美糖尿病病例数预计将从2017 年的4,600 万增加到2045 年的6,200 万人此外，2017 年有4.25 亿人患有糖尿病，预计到2045 年这一数字将达到6.29 亿人。。根据全球癌症观察站 (GLOBOCAN) 2020 年发布的估计，全球报告了 1,930 万癌症病例。美国、中国和印度的病例数明显较高。同样，根据世界卫生组织 2022 年 2 月发布的资料，全球约有 1,000 万人因癌症死亡。癌症发生率的激增表明需要创新的癌症治疗方法。单株抗体是一类有前景的标靶抗癌药物，可增强免疫系统抑制癌细胞活性和消除癌细胞的天然能力。抗体药物偶联物（ADC）在癌症治疗中也显示出有希望的结果。专家、患者、初级保健临床医生和其他医疗保健专业人员对生物相似药高效和安全的认识正在推动其需求。生物相似药已被证明可以改善数百万患者的生活品质。它们是治疗许多疾病的有效且经济高效的选择，包括慢性皮肤病（如牛皮癣和异位性皮肤炎）、肠道疾病（如克罗恩病、肠躁症和结肠炎）、糖尿病、自身免疫性疾病、癌症、肾臟病条件和关节炎。生物相似药开发商正在采用先进的生物加工技术来降低製造成本，这是决定最终消费价格的重要因素。几乎所有生物相似药开发商都在使用现代、尖端的生物加工技术。因此，随着慢性病的日益流行，对治疗危及生命的疾病的生物相似药的需求不断增加，从而推动了对生物加工的需求。

北美生物加工市场概况

遗传和细胞疾病发病率的不断上升导致对细胞疗法的需求不断增加。药物研究和製造商协会(PhRMA) 关于细胞和基因治疗管道的报告（于2020 年发布）显示，目前有400 种细胞和基因疗法正在开发中，用于治疗从癌症到遗传性疾病等多种疾病和病症。 2023 年 4 月，Cytiva 推出了 X 平台生物反应器，以一次性产品简化上游生物加工作业。最初，这些生物反应器的尺寸为 50 L 和 200 L。

生物製药产业的成长主要得益于技术进步、灵活性提高和营运成本低廉，也有利于美国的生物加工市场。根据国际贸易管理局（ITA）的数据，美国是最大的生物製药市场和全球研发领导者。根据PhRMA统计，美国企业占全球生物製药研发工作的近50%，并成功开发出许多拥有智慧财产权的新药。因此，美国生物製药和生物技术公司为改善临床试验结果和确保病患安全而增加的研发投资，以及美国政府不断增加的投资对精准医疗的吸引力日益增强，都有助于美国生物加工市场的成长。

北美生物加工市场收入及 2031 年预测（百万美元）

北美生物加工市场细分

北美生物加工市场按产品、经营规模、製程、应用、最终用户和国家分类。

根据产品，北美生物加工市场分为仪器和消耗品及配件。到2023年，仪器仪表领域将占据更大的市场份额。此外，生物反应器细分分为中试规模、全规模和实验室规模。此外，子分段层析系统又分为液相层析、气相层析等。此外，消耗品和配件细分为试剂、细胞培养基、层析树脂等。

从营运规模来看，北美生物加工市场分为商业营运和临床营运。 2023年，商业营运领域占据更大的市场份额。

依製程划分，北美生物製程市场分为下游生物製程和上游生物製程。到2023年，下游生物製程领域将占据更大的市场份额。

根据应用，北美生物加工市场分为单株抗体、疫苗、重组蛋白、细胞和基因治疗等。 2023 年，单株抗体细分市场占最大市场。

就最终用户而言，北美生物加工市场分为生物製药公司、合约製造组织等。 2023 年，生物製药公司细分市场占最大市场。

按国家/地区划分，北美生物加工市场分为美国、加拿大和墨西哥。 2023 年，美国在北美生物加工市场份额中占据主导地位。

Getinge AB、Thermo Fisher Scientific Inc、Sartorius AG、Corning Inc、Bio-Rad Laboratories Inc、Merck KGaA、3M Co、Eppendorf SE、Repligen Corp、Entegris Inc、Agilent Technologies Inc 和 Cytiva US LLC。是北美生物加工市场上的一些领先公司。

The sedentary life of older people has boosted the prevalence of lifestyle disorders, such as obesity and diabetes. Inherited genes can also express these conditions along with other health concerns such as cardiovascular disease (CVDs), Alzheimer's disease, and depression. As per the National Council on Aging, Inc., 80% of adults (aged 65 and more) are reported to suffer from at least one chronic condition in their lifetime. According to the Centers for Disease Control and Prevention (CDC), approximately 6 of 10 people in the US suffered from at least one serious disease, and 4 of 10 people had two or more chronic conditions in 2020. According to WHO, in 2020, there were more adults over 60 than children under five. The percentage of the global population over 60 will almost double from 12% to 22% between 2015 and 2050. Numerous chronic disorders, such as dementia, osteoarthritis, cancer, stroke, and cardiovascular disease, are known to be associated with aging. CVDs, such as angina pectoris, atherosclerosis, and acute myocardial infarction caused because of hectic lifestyles, are among the significant causes of mortality across the world. As per the World Heart Foundation, mortality caused due to CVD has surged by 60% over the past 30 years (1990-2020). 20.5 million deaths were recorded in 2021 due to CVDs. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can cause various complications in different body parts, thereby increasing the overall risk of death. According to the International Diabetes Federation, the number of diabetic cases in North America is anticipated to grow from 46 million in 2017 to 62 million by 2045. Additionally, 425 million people had diabetes in 2017, and the number is anticipated to reach 629 million by 2045 worldwide, which is an increase of about 35%. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, 19.3 million cancer cases were reported across the world. The number of cases was significantly high in the US, China, and India. Similarly, as per the World Health Organization data published in February 2022, ~10 million people across the world have succumbed to death due to cancer. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody-drug conjugates (ADCs) have also shown promising results in cancer treatment. The recognition of biosimilars as efficient and safe by specialists, patients, primary care clinicians, and other healthcare professionals is propelling its demand. Biosimilars have been proven to improve the quality of life for millions of patients. They are impactful and cost-effective options for treating many diseases, including chronic skin conditions (such as psoriasis and atopic dermatitis), bowel diseases (such as Crohn's disease, irritable bowel syndrome, and colitis), diabetes, autoimmune disease, cancer, kidney conditions, and arthritis. Biosimilar developers are adopting advanced bioprocessing technologies to achieve lower manufacturing costs, which is an important factor in determining the final consumer prices. Nearly all biosimilar developers are using modern, cutting-edge bioprocessing techniques. Therefore, with the growing prevalence of chronic diseases, the demand for biosimilars to treat life-threatening illnesses is spurring, thereby propelling the demand for bioprocessing.

North America Bioprocessing Market Overview

Growing incidences of genetic and cellular disorders are leading to increasing demand for cell therapies. The Pharmaceutical Research and Manufacturers Association (PhRMA)'s report on the cell & gene therapy pipeline (published in 2020), revealed that there are 400 cell and gene therapies in development for targeting a variety of diseases and conditions from cancer to genetic disorders to neurologic conditions in the US. In April 2023, Cytiva launched X-platform bioreactors to simplify upstream bioprocessing operations with single-use products. Initially, these bioreactors were available in the sizes of 50 L and 200 L. The X-Platform bioreactors are now equipped with Figurate automation solution software, and they can increase process efficiency through ergonomic improvements, production capacity, and simplified supply chain operations.

The growth of the biopharmaceutical sector, mainly due to technological advancements, increasing flexibility, and low operational costs, also benefits the bioprocessing market in the US. As per the International Trade Administration (ITA), the US is the largest market for biopharmaceuticals and the global leader in R&D. According to the PhRMA, companies in the US account for nearly 50% of the global biopharmaceutical R&D work, and they have succeeded in developing many novel medicines for which they hold intellectual property rights. Thus, the increasing R&D investments by US-based biopharmaceutical and biotechnology companies to improve outcomes of clinical trials and ensure patient safety, and the growing traction toward precision medicine with rising investments by the US government contribute to the growth of the bioprocessing market in the US.

North America Bioprocessing Market Revenue and Forecast to 2031 (US$ Million)

North America Bioprocessing Market Segmentation

The North America bioprocessing market is categorized into product, scale of operation, process, application, end user, and country.

Based on product, the North America bioprocessing market is bifurcated into instruments and consumables & accessories. The instruments segment held a larger market share in 2023. Furthermore, the instruments segment is sub segmented into filtration devices, bioreactors, chromatography systems, centrifuge, drying devices, and others. Additionally, the bioreactors subsegment is categorized into pilot scale, full scale, and laboratory scale. Furthermore, the sub segment chromatography systems is segmented into liquid chromatography, gas chromatography, and others. Additionally, the consumables & accessories segment is sub segmented into reagents, cell culture media, chromatography resins, and others.

In terms of scale of operation, the North America bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held a larger market share in 2023.

By process, the North America bioprocessing market is bifurcated into downstream bioprocess and upstream bioprocess. The downstream bioprocess segment held a larger market share in 2023.

Based on application, the North America bioprocessing market is categorized into monoclonal antibodies, vaccines, recombinant protein, cell & gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of end user, the North America bioprocessing market is categorized into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies segment held the largest market share in 2023.

By country, the North America bioprocessing market is segmented into the US, Canada, and Mexico. The US dominated the North America bioprocessing market share in 2023.

Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc, Merck KGaA, 3M Co, Eppendorf SE, Repligen Corp, Entegris Inc, Agilent Technologies Inc, and Cytiva US LLC. are some of the leading companies operating in the North America bioprocessing market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Bioprocessing Market Landscape

4.1 Ecosystem Analysis
- 4.1.1 List of Vendors in the Value Chain

5. North America Bioprocessing Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Chronic Diseases
- 5.1.2 Growing Biopharmaceutical Industry
5.2 Market Restraints
- 5.2.1 Stringent Regulatory Policies and Limitations Associated with Bioprocessing
5.3 Market Opportunities
- 5.3.1 Proliferating Demand for Personalized Medicine
5.4 Future Trends
- 5.4.1 Shift Toward Automated Cell Therapy Manufacturing
5.5 Impact of Drivers and Restraints:

6. Bioprocessing Market - North America Analysis

6.1 Bioprocessing Market Revenue (US$ Million), 2021-2031

7. North America Bioprocessing Market Analysis - by Product

7.1 Overview
7.2 Instruments
- 7.2.1 Overview
- 7.2.2 Instruments: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.2.2.1 Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Instruments
    - 7.2.2.1.1 Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Bioreactors
    - 7.2.2.1.2 Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Chromatography Systems
7.3 Consumables & Accessories
- 7.3.1 Overview
- 7.3.2 Consumables & Accessories: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.3.2.1 Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Consumables & Accessories

8. North America Bioprocessing Market Analysis - by Scale of Operation

8.1 Overview
8.2 Commercial Operations
- 8.2.1 Overview
- 8.2.2 Commercial Operations: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Clinical Operations
- 8.3.1 Overview
- 8.3.2 Clinical Operations: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Bioprocessing Market Analysis - by Process

9.1 Overview
9.2 Downstream Bioprocess
- 9.2.1 Overview
- 9.2.2 Downstream Bioprocess: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Upstream Bioprocess
- 9.3.1 Overview
- 9.3.2 Upstream Bioprocess: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Bioprocessing Market Analysis - by Application

10.1 Overview
10.2 Monoclonal Antibodies
- 10.2.1 Overview
- 10.2.2 Monoclonal Antibodies: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Vaccines
- 10.3.1 Overview
- 10.3.2 Vaccines: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
10.4 Recombinant Protein
- 10.4.1 Overview
- 10.4.2 Recombinant Protein: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
10.5 Cell & Gene Therapy
- 10.5.1 Overview
- 10.5.2 Cell & Gene Therapy: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
10.6 Others
- 10.6.1 Overview
- 10.6.2 Others: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Bioprocessing Market Analysis - by End User

11.1 Overview
11.2 Biopharmaceutical Companies
- 11.2.1 Overview
- 11.2.2 Biopharmaceutical Companies: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
11.3 Contract Manufacturing Organization
- 11.3.1 Overview
- 11.3.2 Contract Manufacturing Organization: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
11.4 Others
- 11.4.1 Overview
- 11.4.2 Others: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)

12. North America Bioprocessing Market - Country Analysis

12.1 North America: Bioprocessing Market Overview
- 12.1.1 North America: Bioprocessing Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.1 United States: Bioprocessing Market- Revenue and Forecast to 2031 (US$ Million)
  - 12.1.1.2 Overview
  - 12.1.1.3 United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.3.1 United States: Bioprocessing Market Breakdown, by Product
    - 12.1.1.3.1.1 United States: Bioprocessing Market Breakdown, by Instruments
    - 12.1.1.3.1.1.1 United States: Bioprocessing Market Breakdown, by Bioreactors
    - 12.1.1.3.1.1.2 United States: Bioprocessing Market Breakdown, by Chromatography Systems
    - 12.1.1.3.1.2 United States: Bioprocessing Market Breakdown, by Consumables & Accessories
    - 12.1.1.3.2 United States: Bioprocessing Market Breakdown, by Scale of Operation
    - 12.1.1.3.3 United States: Bioprocessing Market Breakdown, by Process
    - 12.1.1.3.4 United States: Bioprocessing Market Breakdown, by Application
    - 12.1.1.3.5 United States: Bioprocessing Market Breakdown, by End User
  - 12.1.1.4 Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.4.1 Overview
  - 12.1.1.5 Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.5.1 Canada: Bioprocessing Market Breakdown, by Product
    - 12.1.1.5.1.1 Canada: Bioprocessing Market Breakdown, by Instruments
    - 12.1.1.5.1.1.1 Canada: Bioprocessing Market Breakdown, by Bioreactors
    - 12.1.1.5.1.1.2 Canada: Bioprocessing Market Breakdown, by Chromatography Systems
    - 12.1.1.5.1.2 Canada: Bioprocessing Market Breakdown, by Consumables & Accessories
    - 12.1.1.5.2 Canada: Bioprocessing Market Breakdown, by Scale of Operation
    - 12.1.1.5.3 Canada: Bioprocessing Market Breakdown, by Process
    - 12.1.1.5.4 Canada: Bioprocessing Market Breakdown, by Application
    - 12.1.1.5.5 Canada: Bioprocessing Market Breakdown, by End User
  - 12.1.1.6 Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.6.1 Overview
  - 12.1.1.7 Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.7.1 Mexico: Bioprocessing Market Breakdown, by Product
    - 12.1.1.7.1.1 Mexico: Bioprocessing Market Breakdown, by Instruments
    - 12.1.1.7.1.1.1 Mexico: Bioprocessing Market Breakdown, by Bioreactors
    - 12.1.1.7.1.1.2 Mexico: Bioprocessing Market Breakdown, by Chromatography Systems
    - 12.1.1.7.1.2 Mexico: Bioprocessing Market Breakdown, by Consumables & Accessories
    - 12.1.1.7.2 Mexico: Bioprocessing Market Breakdown, by Scale of Operation
    - 12.1.1.7.3 Mexico: Bioprocessing Market Breakdown, by Process
    - 12.1.1.7.4 Mexico: Bioprocessing Market Breakdown, by Application
    - 12.1.1.7.5 Mexico: Bioprocessing Market Breakdown, by End User

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in the Bioprocessing Market
13.3 Inorganic Growth Strategies
- 13.3.1 Overview
13.4 Organic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Getinge AB
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Thermo Fisher Scientific Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sartorius AG
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Corning Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Bio-Rad Laboratories Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Merck KGaA
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 3M Co
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Eppendorf SE
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Repligen Corp
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Entegris Inc
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
14.11 Agilent Technologies Inc
- 14.11.1 Key Facts
- 14.11.2 Business Description
- 14.11.3 Products and Services
- 14.11.4 Financial Overview
- 14.11.5 SWOT Analysis
- 14.11.6 Key Developments
14.12 Cytiva US LLC
- 14.12.1 Key Facts
- 14.12.2 Business Description
- 14.12.3 Products and Services
- 14.12.4 Financial Overview
- 14.12.5 SWOT Analysis
- 14.12.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America Bioprocessing Market Segmentation
Table 2. List of Vendors
Table 3. Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Instruments
Table 4. Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Bioreactors
Table 5. Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Chromatography Systems
Table 6. Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Consumables & Accessories
Table 7. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 8. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Instruments
Table 9. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Bioreactors
Table 10. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Chromatography Systems
Table 11. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Consumables & Accessories
Table 12. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Scale of Operation
Table 13. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Process
Table 14. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 15. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 16. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 17. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Instruments
Table 18. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Bioreactors
Table 19. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Chromatography Systems
Table 20. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Consumables & Accessories
Table 21. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Scale of Operation
Table 22. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Process
Table 23. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 24. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 25. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 26. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Instruments
Table 27. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Bioreactors
Table 28. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Chromatography Systems
Table 29. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Consumables & Accessories
Table 30. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Scale of Operation
Table 31. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Process
Table 32. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 33. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 34. Recent Inorganic Growth Strategies in the Bioprocessing Market
Table 35. Recent Organic Growth Strategies in the Bioprocessing Market
Table 36. Glossary of Terms, Bioprocessing Market

List Of Figures

Figure 1. North America Bioprocessing Market Segmentation, by Country
Figure 2. Bioprocessing Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Bioprocessing Market Revenue (US$ Million), 2021-2031
Figure 5. Bioprocessing Market Share (%) - by Product (2023 and 2031)
Figure 6. Instruments: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Consumables & Accessories: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Bioprocessing Market Share (%) - by Scale of Operation (2023 and 2031)
Figure 9. Commercial Operations: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. Clinical Operations: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. Bioprocessing Market Share (%) - by Process (2023 and 2031)
Figure 12. Downstream Bioprocess: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Upstream Bioprocess: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Bioprocessing Market Share (%) - by Application (2023 and 2031)
Figure 15. Monoclonal Antibodies: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. Vaccines: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Recombinant Protein: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Cell & Gene Therapy: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Others: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Bioprocessing Market Share (%) - by End User (2023 and 2031)
Figure 21. Biopharmaceutical Companies: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Contract Manufacturing Organization: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. North America: Bioprocessing Market, by Key Country - Revenue (2023) (US$ Million)
Figure 25. North America: Bioprocessing Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 26. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 29. Growth Strategies in the Bioprocessing Market